Relafen

• Anti-Infective Agents
• Enzyme Inhibitors
• ATC:J01MB02

• Arthaxan
• Balmox
• Consolan
• Dolsinal
• Flambate
• Listran
• Mebutan
• Nabumetona
• Nabumetone [USAN:BAN:INN:JAN]
• Nabumetonum [INN-Latin]
• Nabuser
• Prodac
• Relafen
• Relif
• Relifen
• Relifex
• Unimetone

• No information avaliable

C₁₂H₁₂N₂O₃

http://www.rxlist.com/cgi/generic2/nalidixicacid.htm

Relafen FDA

Relafen MSDS

No information avaliable

232.235 g/mol

229.5 ^oC

100 mg/L

Solid

0.949

Suspension (250 mg/5 mL tsp); Tablets (1000 mg, 500 mg, 250 mg)

For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.

Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. Nalidixic acid is bactericidal and is effective over the entire urinary pH range. Conventional chromosomal resistance to nalidixic acid taken in full dosage has been reported to emerge in approximately 2 to 14 percent of patients during treatment; however, bacterial resistance to nalidixic acid has not been shown to be transferable via R factor.

Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.

ORAL (LD₅₀): Acute: 1160 mg/kg [Rat]. 572 mg/kg [Mouse]. Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.

Enteric bacteria and other eubacteria